What’s New

Latest News

Phase 3 Randomized Clinical Trial
TACE Plus Ablation Improves Survival in Unresectable HCC Compared With TACE Alone
08/11/2026
Laura Simson, MA
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency...
08/11/2026
Vascular Disease Management
Vascular Disease Management
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
Oncology
News
The VA Announces New Trial Assessing the Impact of Psilocybin in Veterans With Major Depressive Disorder
08/10/2026
Rebecca Amrick
The US Department of Veterans Affairs (VA) recently announced the launch of a new clinical trial that will examine the effectiveness and safety of psilocybin in veterans with treatment-resistant major depressive disorder.
The US Department of Veterans Affairs (VA) recently announced the launch of a new clinical trial that will examine the effectiveness and safety of psilocybin in veterans with treatment-resistant major depressive disorder.
The US Department of Veterans...
08/10/2026
Veterans Health Today
Veterans Health Today
News
The Current Treatment Landscape for Myelofibrosis
08/10/2026
Rebecca Amrick
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a...
08/10/2026
Journal of Clinical Pathways
Journal of Clinical Pathways
News
Omalizumab Demonstrates Improved Efficacy and Safety Among Patients With Angioedema
08/10/2026
Rebecca Amrick
Researchers found that omalizumab demonstrated favorable efficacy and safety in treating patients with mast cell–mediated angioedema (AE-MC), indicating that AE-MC can be managed similarly to chronic spontaneous urticaria (CSU).
Researchers found that omalizumab demonstrated favorable efficacy and safety in treating patients with mast cell–mediated angioedema (AE-MC), indicating that AE-MC can be managed similarly to chronic spontaneous urticaria (CSU).
Researchers found that...
08/10/2026
First Report Managed Care
First Report Managed Care
US FDA sign
News
FDA Approves Oveporexton for Adults With Narcolepsy Type 1
08/06/2026
Brionna Mendoza
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved...
08/06/2026
Psych Congress Network
Psych Congress Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network
Pharmacy Learning Network

Latest Research

July/August 2026
The Dermatologist
Ultrasound as a Transformative Tool in Dermatology
Vol. 34, Issue 5, Issue August 2026
EMS World Summer 2026 Issue
EMSWorld
Managing Menacing Maternal Mishaps
Vol. 55, Issue 2, Issue August 2026

HMP Global Learning Network

Featured Interviews

Amy paller
Videos
Clinical Management of Atopic Dermatitis Across Childhood
08/01/2026
Amy S. Paller, MD, MS; Riya Gandhi, MA
Dr Amy Paller discusses how advances in understanding type 2 inflammation are transforming pediatric atopic dermatitis care.
Dr Amy Paller discusses how advances in understanding type 2 inflammation are transforming pediatric atopic dermatitis care.
Dr Amy Paller discusses how...
08/01/2026
The Dermatologist
Murugiah_title_slide
Author Interview
Adoption of Intravascular Imaging Use Among Intermediate to High-Volume Operators in the United States From 2019 to 2023: A Medicare Data Analysis — An Interview With Karthik Murugiah, MBBS, MHS
07/31/2026
Karthik Murugiah, MBBS, MHS
Dr Karthik Murugiah shares background and insights on his article, “Adoption of Intravascular Imaging Use Among Intermediate to High-Volume Operators in the United States From 2019 to 2023: A Medicare Data Analysis.”
Dr Karthik Murugiah shares background and insights on his article, “Adoption of Intravascular Imaging Use Among Intermediate to High-Volume Operators in the United States From 2019 to 2023: A Medicare Data Analysis.”
Dr Karthik Murugiah shares...
07/31/2026
Journal of Invasive Cardiology
Erin Crown, MHS, PA-C, CAQ-Psychiatry
Clinical Pearls
When to Adjust or Augment Antidepressant Treatment in MDD
07/31/2026
Erin Crown, MHS, PA-C, CAQ
In this video, Erin Crown, MHS, PA-C, CAQ-Psychiatry, shares her approach to deciding when to augment rather than switch antidepressant therapy. 
In this video, Erin Crown, MHS, PA-C, CAQ-Psychiatry, shares her approach to deciding when to augment rather than switch antidepressant therapy. 
In this video, Erin Crown, MHS,...
07/31/2026
Psych Congress NP Institute
Thumbnail
Videos
How to Implement Subcutaneous Immunotherapy for Providers
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to...
07/30/2026
Oncology
Bruce Sands
Expert Insights
Bruce Sands, MD, on Results from DUET-CD
07/19/2026
Bruce E. Sands, MD, MS
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of...
07/19/2026
Advances in Inflammatory Bowel Disease Network
Part 5 panel
Videos
Safety Monitoring in High-Risk CSCC
06/24/2026
Christopher Barker, MD; Krupal Patel, MD, MSc, FRCSC, FACS; John Strasswimmer, MD, PhD, FAAD, FACMS; Deborah J.L. Wong, MD, PhD
The roundtable discussion concludes with a review of the safety profile of adjuvant cemiplimab and best practices for monitoring and managing adverse events in patients with high-risk CSCC, with an emphasis on multidisciplinary follow-up,...
The roundtable discussion concludes with a review of the safety profile of adjuvant cemiplimab and best practices for monitoring and managing adverse events in patients with high-risk CSCC, with an emphasis on multidisciplinary follow-up,...
The roundtable discussion...
06/24/2026
The Dermatologist
Oncology Learning Network Live Daily
Discussion: CAR-T Cell Therapy Access and Earlier Referral
06/19/2026
Beth Faiman, CNP, PhD; Donna Catamero, ANP-BC, OCN, CCRC
Clinicians discuss key updates in multiple myeloma and plasma cell disorders.
Clinicians discuss key updates in multiple myeloma and plasma cell disorders.
Clinicians discuss key updates...
06/19/2026
Oncology
Pediatric Video Tutorial: The Future of 'Color Coding' Kids
Videos
Pediatric Video Tutorial: The Future of 'Color Coding' Kids
06/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Variations of the Broselow tape have been in use for almost 40 years. Variations of Handtevy have been in use for over 15 years. Let’s use our crystal ball to gaze into the very near future of color coding kids.
Variations of the Broselow tape have been in use for almost 40 years. Variations of Handtevy have been in use for over 15 years. Let’s use our crystal ball to gaze into the very near future of color coding kids.
Variations of the Broselow tape...
06/19/2026
EMSWorld
pediatric asthma
Videos
Pediatric Video Tutorial: Pediatric Asthma
05/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good,...
05/19/2026
EMSWorld
CTP News Desk Image
Viewpoints
Skin Substitute Reimbursement Changes 2026: MAC Denials, Q Codes, and What’s Next
05/19/2026
Daniel L. Kapp, MD
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his...
05/19/2026
Wounds

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use